Is the Fas/Fas-L pathway a promising target for treating inflammatory heart disease?

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 2, 2009, Pages 94-99

  Henriques Pons, Andréa ^a,b   De Oliveira, Gabriel Melo ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b NONE   (Brazil)

Author keywords

Fas Fas L; Inflammation; Myocarditis; Treatment therapy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; B7 ANTIGEN; CASPASE; CASPASE 10; CASPASE 8; CD18 ANTIGEN; CHEMOKINE; CYTOKINE; DAXX PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS ASSOCIATED FACTOR 1; FAS ASSOCIATED PHOSPHATASE; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL TRISPHOSPHATE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FIST; PROTEIN HIPK3; RECEPTOR INTERACTING PROTEIN 140; STRESS ACTIVATED PROTEIN KINASE; SUMO PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; ANTIBODY;

AUTOIMMUNE DISEASE; BINDING SITE; CELL DEATH; CELL FUNCTION; CHEMOTAXIS; CYTOKINE RELEASE; DRUG TARGETING; HEART DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; MOLECULAR INTERACTION; MOLECULAR THERAPY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; ANIMAL; APOPTOSIS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; MYOCARDITIS;

EID: 65549136073     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318198fe46     Document Type: Review

References (75)

1. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178. (Pubitemid 24006113)
2. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29-55.
3. Cascino I, Fiucci G, Papoff G, et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706-2713.
4. Sano H, Asano K, Minatoguchi S, et al. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Nephron. 1998;80:153-161. (Pubitemid 28458790)
5. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428-1440. (Pubitemid 36177050)
6. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998; 396:699-703.
7. LiW, Zhang C, Chen C, et al. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol. 2007;4:455-460.
8. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187: 1205-1213. (Pubitemid 28189110)
9. Sato T, Hirasawa A, Kawabuchi Y, et al. Cellular expressions and serum concentrations of Fas ligand and Fas receptor in patients with infectious mononucleosis. Int J Hematol. 2000;72:329-336.
10. Nada O, Abdel-Hamid M, Ismail A, et al. The role of the tumor necrosis factor (TNF)-Fas L and HCV in the development of hepatocellular carcinoma. J Clin Virol. 2005;34:140-146. (Pubitemid 41278616)
11. Silvestris F, Cafforio P, Camarda G, et al. Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. Int J Clin Lab Res. 1998;28:215-225. (Pubitemid 128514836)
12. Seino K, Iwabuchi K, Kayagaki N, et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol. 1998;161:4484-4488. (Pubitemid 28492016)
13. Ottonello L, Tortolina G, Amelotti M, et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol. 1999;162:3601-3606. (Pubitemid 29313614)
14. Dupont PJ,Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology. 2007;120:133-139.
15. Giroux M, Denis F. CD1d-unrestricted human NKT cells release chemokines upon Fas engagement. Blood. 2005;105:703-710. (Pubitemid 40070756)
16. Zanin-Zhorov A, Hershkoviz R, Hecht I, et al. Fibronectin-associated Fas ligand rapidly induces opposing and time-dependent effects on the activation and apoptosis of T cells. J Immunol. 2003;171:5882-5889. (Pubitemid 37467205)
17. Lambert C, Landau AM, Desbarats J. Fas-beyond death: a regenerative role for Fas in the nervous system. Apoptosis. 2003;8:551-562. (Pubitemid 37411739)
18. Chan FK, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351-2354. (Pubitemid 30448156)
19. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579-5588.
20. Chang HY, Yang X, Baltimore D. Dissecting Fas signaling with an alteredspecificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc Natl Acad Sci U S A. 1999;96:1252-1256. (Pubitemid 29098437)
21. Chu K, Niu X, Williams LT. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc Natl Acad Sci U S A. 1995;92: 11894-11898. (Pubitemid 26014216)
22. Sato T, Irie S, Kitada S, et al. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science. 1995;268:411-415.
23. Okura T, Gong L, Kamitani T, et al. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol. 1996;157:4277-4281. (Pubitemid 126449343)
24. Rochat-Steiner V, Becker K, Micheau O, et al. FIST/HIPK3: a Fas/FADDinteracting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J Exp Med. 2000;192:1165-1174.
25. Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 2005;30:151-159. (Pubitemid 40332531)
26. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol. 2003;15:725-731.
27. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14:10-22. (Pubitemid 44911890)
28. Zhang J, Cado D, Chen A, et al. Fas-mediated apoptosis and activationinduced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392:296-300. (Pubitemid 28155104)
29. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fasmediated apoptosis. Cell Signal. 2003;15:983-992.
30. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33-42.
31. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195. (Pubitemid 27297457)
32. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol. 2000;10:640-648. (Pubitemid 30354699)
33. Michaelson JS. The Daxx enigma. Apoptosis. 2000;5:217-220.
34. Salomoni P, Khelifi AF. Daxx: death or survival protein? Trends Cell Biol. 2006;16:97-104.
35. Hollenbach AD, McPherson CJ, Mientjes EJ, et al. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J Cell Sci. 2002; 115(Pt 16):3319-3330.
36. Raoul C, Estévez AG, Nishimune H, et al. Motoneuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations. Neuron. 2002;35:1067-1083.
37. Guo Z, Zhang M, Tang H, et al. Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood. 2005;106:2033-2041. (Pubitemid 41291717)
38. Miwa K, Asano M, Horai R, et al. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 1998;4:1287-1292. (Pubitemid 28512110)
39. Biancone L, Martino AD, Orlandi V, et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med. 1997;186: 147-152. (Pubitemid 27304857)
40. Huber SA, Born W, O'Brien R. Dual functions of murine gammadelta cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vgamma1+ and Vgamma4+ cells. Microbes Infect. 2005;7:537-543. (Pubitemid 40603454)
41. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest. 1999;104:13-19. (Pubitemid 29534340)
42. DosReis GA, Borges VM, Zin WA. The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med. 2004;8: 285-293.
43. Borges VM, Falcão H, Leite-Júnior JH, et al. Fas ligand triggers pulmonary silicosis. J Exp Med. 2001;194:155-164.
44. Bhuiyan MS, Takada Y, Shioda N, et al. Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICEinhibitory protein. Cardiovasc Ther. 2008;26:10-23.
45. Aprahamian T, Rifkin I, Bonegio R, et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med. 2004;199:1121-1131. (Pubitemid 38619908)
46. Zhang H, Yang Y, Horton JL, et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest. 1997; 100:1951-1957. (Pubitemid 27459348)
47. Kim SH, Kim S, Oligino TJ, et al. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther. 2002;6: 584-590. (Pubitemid 35363690)
48. Kim SH, Bianco N, Menon R, et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther. 2006;13:289-300. (Pubitemid 43056894)
49. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol. 2008;3:127-155.
50. Wasi F, Shuter J. Primary bacterial infection of the myocardium. Front Biosci. 2003;8:s228-s231.
51. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest. 2002; 122:302-310.
52. Lopes MF, Nunes MP, Henriques-Pons A, et al. Increased susceptibility of Fas ligand-deficient gld mice to Trypanosoma cruzi infection due to a Th2-biased host immune response. Eur J Immunol. 1999;29:81-89. (Pubitemid 29043525)
53. Binah O, Shilkrut M, Yaniv G, et al. The Fas receptor-1,4,5-IP3 cascade: a potential target for treating heart failure and arrhythmias. Ann N Y Acad Sci. 2004;1015:338-350.
54. Nelson DP, Setser E, Hall DG, et al. Proinflammatory consequences of transgenic Fas ligand expression in the heart. J Clin Invest. 2000;105: 1199-1208. (Pubitemid 30266072)
55. Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest. 2002;109:373-381. (Pubitemid 34141811)
56. Sheppard R, Bedi M, Kubota T, et al; for the IMAC Investigators. Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol. 2005;46: 1036-1042. (Pubitemid 41316512)
57. de Oliveira GM, Diniz RL, Batista W, et al. Fas ligand-dependent inflammatory regulation in acute myocarditis induced by Trypanosoma cruzi infection. Am J Pathol. 2007;171:79-86. (Pubitemid 47339228)
58. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113:876-890. (Pubitemid 43754310)
59. Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev. 2007;15:170-177.
60. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. 1987;18:619-624.
61. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113:593-595.
62. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269-275.
63. Liu C, Chen J, Liu K. Immunosuppressive treatment for inflammatory cardiomyopathy: meta-analysis of randomized controlled trials. Int Heart J. 2005;46:113-122.
64. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857-863. (Pubitemid 36241044)
65. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061-1068. (Pubitemid 19256658)
66. Udi N, Yehuda S. Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases. Autoimmun Rev. 2008;7:445-452.
67. Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7:440-444.
68. Yuan Z, Liu Y, Liu Y, et al. Cardioprotective effects of peroxisome proliferator activated receptor gamma activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor kappaB blockade. Heart. 2005;91:1203-1208. (Pubitemid 41192401)
69. Aruffo A, Hollenbaugh D. Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr Opin Immunol. 2001;13:683-686. (Pubitemid 33000162)
70. Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol. 2002;27:591-596. (Pubitemid 35463876)
71. González-Amaro R, Mittelbrunn M, Sánchez-Madrid F. Therapeutic antiintegrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords? Immunology. 2005;116:289-296.
72. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806-809. (Pubitemid 23261761)
73. Niu J, Azfer A, Deucher MF, et al. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. J Mol Cell Cardiol. 2006;40:810-820. (Pubitemid 43817041)
74. Barac YD, Zeevi-Levin N, Yaniv G, et al. The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res. 2005;68:75-86.
75. Shilkrut M, Yaniv G, Asleh R, et al. Tyrosine kinases inhibitors block Fasmediated deleterious effects in normoxic and hypoxic ventricular myocytes. J Mol Cell Cardiol. 2003;35:1229-1240. (Pubitemid 37168091)